Experic, a US-based contract development and manufacturing organization (CDMO) and clinical trial supply services company serving the global biopharmaceutical industry, has announced a significant growth capital investment led by 1315 Capital, a Philadelphia-based, growth equity firm focused on healthcare, with participation from its existing investors including East Seattle Partners, Harro Höfliger Packaging Systems, Inc. and Kineticos Ventures.
 
The new capital injection will enable Experic to further enhance its manufacturing capabilities, accelerate its international expansion plans, and support its mission to deliver high-quality, agile services to the biopharmaceutical sector. As the biopharmaceutical industry continues to evolve, this partnership with 1315 Capital positions Experic to meet the growing demands for advanced drug development, manufacturing, and clinical trial supply solutions.
 
“We are excited to join the 1315 Capital portfolio. The firm’s deep expertise in healthcare and proven track record for strategic investments align with our vision for Experic’s growth and expansion of technical capabilities,” said David Wood, CEO and Chairman of Experic. “This investment will empower us to continue delivering innovative solutions and white glove service that meet our clients’ needs while expanding our footprint in the global biopharma market.”
 
“Biopharmaceutical companies are increasingly relying on specialized partners to help develop and manufacture their innovative products. Experic’s differentiated expertise, including its unique capability handling low dose powders, and flexible, customer orientated approach address a growing need in the market,” said Matt Reber, Partner at 1315 Capital. “We are excited to partner with Experic as they continue to expand their capabilities and global reach.”